Join Isogenica at Discovery on Target
Isogenica is excited to announce its attendance at Discovery on Target 2021 September 27-30th
Isogenica’s Associate Director of Antibody Alliances, Marion Cubitt, will be attending Discovery on Target 2021 virtually on September 27-30th.
Marion will be presenting the latest Isogenica VHH data on ‘Synthetically-Derived PD-1 Antagonising VHHs Bind in Monomer and Multimer Formats to PD-L1-Expressing Breast Cancer Cells‘.
Do not miss out on the opportunity to have a live conversation with Marion at the
VIRTUAL POSTER CHAT (13:15 – 13:45 EDT, 29th Sept)
to discuss VHH applications in multiple formats such as bi-specifics and how you could apply Isogenica’s technology in your projects.
If Isogenica VHH antibodies have application in your discovery projects or you would like to learn more about partnering with Isogenica, get in touch and we will be glad to schedule a meeting.
Isogenica has developed LlamdA™ (single domain VHH) therapeutic antibodies from its proprietary fully synthetic antibody libraries and leveraging its CIS Display and Colibra™ technologies to accelerate the discovery and development process. Over the last four years Isogenica has entered into eight significant partnerships, leveraging its libraries, technologies and expertise to build a broad pipeline of programs that are now advancing into pre-clinical and early clinical development with our partners.”
T +44 1799 533 680